View ValuationKromek Group 향후 성장Future 기준 점검 0/6Kromek Group 의 수익과 수익은 각각 연간 11.9% 및 134.7% 감소할 것으로 예상됩니다 while EPS는 연간 133.7% 만큼 쇠퇴할 것으로 예상됩니다.핵심 정보-134.7%이익 성장률-133.71%EPS 성장률Semiconductor 이익 성장30.4%매출 성장률-11.9%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트12 May 2026최근 향후 성장 업데이트공시 • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.공시 • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.공시 • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.공시 • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Rakesh Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.공시 • Dec 16Kromek Group plc to Report First Half, 2026 Results on Jan 20, 2026Kromek Group plc announced that they will report first half, 2026 results on Jan 20, 2026공시 • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.공시 • Oct 03+ 1 more updateKromek Group plc, Annual General Meeting, Oct 27, 2025Kromek Group plc, Annual General Meeting, Oct 27, 2025. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham ts21 3ff, sedgefield United Kingdom공시 • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.공시 • May 10+ 1 more updateKromek Group plc Announces CFO Changes, Effective 1 June 2025Kromek Group plc announced that Claire Burgess will be appointed as Chief Financial Officer ("CFO") of the Group, effective June 1, 2025. Claire Burgess has spent over 12 years in senior financial positions in businesses in the UK and US, primarily in the engineering and technology sectors. Most recently, Ms. Burgess was Financial Director of Advanced Electric Machines Group Ltd. ("AEM"), a designer and manufacturer of magnet-free electric powertrain technologies. Other experience includes being CFO of group companies JB Processing and TBGS Holdings and being responsible for establishing and building the US subsidiaries, including the acquisition of the Alabama White Marble Quarry. She is a qualified Fellow Chartered Accountant, having begun her career as an auditor at Ernst & Young before joining KPMG as a Corporate Finance Executive. Paul Farquhar is retiring and will therefore resign as CFO of the Group, effective June 1, 2025. Claire Burgess, aged 51, Current directorships and/or partnerships Former directorships and/or partnerships (within the last 5 years): Advanced Electric Machines Group Limited; Advanced Electric Machines Limited; Advanced Electric Machines Research Limited; Inn Collection (Bassenthwaite) Limited; Inn Collection Lakes (Ambleside) Limited; Inn Collection (Whitby) Limited; Inn Collection (Northallerton) Limited; Inn Collection (Helmsley) Limited; Inn Collection (Seaburn) Limited; Inn Collection Lakes (Coniston) Limited; Vindolanda Bidco Limited; Lindisfarne Inns Limited; Inn Collection Limited; Inn Collection AcquisitionCo Limited; Inn Collection Topco Limited; Inn Collection Midco Limited; Durham Vale Developments Limited; Vindolanda Midco 1 Limited; Marshall Inns Limited; Greensfield Moor Development Limited; Lindisfarne Inns (Bamburgh Castle) Limited; Inn Collection Bidco Limited; Vindolanda Topco Limited; Vindolanda Midco 2 Limited; Inn Collection Management Limited; and Inn Collection Lakes (Ambleside) Limited.공시 • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.공시 • Nov 19Kromek Group plc, Annual General Meeting, Dec 13, 2024Kromek Group plc, Annual General Meeting, Dec 13, 2024. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham, ts21 3ff, sedgefield United KingdomNew Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£7.8m). Currently unprofitable and not forecast to become profitable next year (UK£3.4m net loss next year). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Market cap is less than US$100m (€50.6m market cap, or US$54.2m).Buy Or Sell Opportunity • Oct 29Now 24% overvaluedOver the last 90 days, the stock has fallen 1.5% to €0.066. The fair value is estimated to be €0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to decline by 3.2% in the next year.Reported Earnings • Oct 28Full year 2024 earnings released: UK£0.006 loss per share (vs UK£0.014 loss in FY 2023)Full year 2024 results: UK£0.006 loss per share (improved from UK£0.014 loss in FY 2023). Revenue: UK£19.4m (up 12% from FY 2023). Net loss: UK£3.29m (loss narrowed 46% from FY 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.New Risk • Aug 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.6m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (€41.0m market cap, or US$45.2m).Board Change • Mar 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Wilks was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.이익 및 매출 성장 예측DB:4KM - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수4/30/20273011824/30/202627216210/31/202538131317N/A7/31/20253281217N/A4/30/20252741116N/A1/31/202521-137N/A10/31/202416-6-6-1N/A7/31/202418-5-7-2N/A4/30/202419-3-8-3N/A1/31/202419-4-50N/A10/31/202318-4-33N/A7/31/202317-5-41N/A4/30/202317-6-50N/A1/31/202316-7-8-3N/A10/31/202214-8-11-5N/A7/31/202213-6-11-4N/A4/30/202212-5-10-4N/A1/31/202211-5-9-3N/A10/31/202110-5-8-2N/A7/31/202110-5-8-1N/A4/30/202110-5-7-1N/A1/31/202111-11-8-1N/A10/31/202012-17-9-1N/A7/31/202013-17-110N/A4/30/202013-17-120N/A1/31/202015-9-13-2N/A10/31/201916-1-13-4N/A7/31/201915-1N/A-4N/A4/30/201915-1N/A-5N/A1/31/201913-1N/A-5N/A10/31/201811-2N/A-5N/A7/31/201811-1N/A-5N/A4/30/201812-1N/A-5N/A1/31/201811-2N/A-4N/A10/31/201710-3N/A-4N/A7/31/20179-3N/A-3N/A4/30/20179-3N/A-1N/A1/31/20179-2N/A-1N/A10/31/20169-1N/A0N/A7/31/20169-2N/A-1N/A4/30/20168-2N/A-3N/A1/31/20168-2N/A-3N/A10/31/20158-3N/A-3N/A7/31/20158-2N/A-3N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 4KM 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -134.7%).수익 vs 시장: 4KM 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -134.7%).고성장 수익: 4KM 의 수익은 향후 3년간 감소할 것으로 예상됩니다.수익 대 시장: 4KM 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -11.9%).고성장 매출: 4KM 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -11.9%).주당순이익 성장 예측향후 자기자본이익률미래 ROE: 4KM의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YSemiconductors 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 21:02종가2026/05/22 00:00수익2025/10/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Kromek Group plc는 1명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael MitchellCavendish
공시 • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.
공시 • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.
공시 • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.
공시 • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Non-Executive Chairman Rakesh Sharma was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • May 14Kromek Group plc Provides Earnings Guidance for the 12-Month Period Ended 30 April 2026Kromek Group plc provided earnings guidance for the 12-month period ended 30 April 2026. For the period, the company estimates to be revenues of £27.2 million in line with market expectations.
공시 • Dec 16Kromek Group plc to Report First Half, 2026 Results on Jan 20, 2026Kromek Group plc announced that they will report first half, 2026 results on Jan 20, 2026
공시 • Oct 28Kromek Group plc Provides earnings Guidance for the First Half of 2026Kromek Group plc provided earnings guidance for the first half of 2026. For the first half, the group expects to report revenue of at least £14.5m (H1 2025: £3.7m). This includes revenue generated under the Group's enablement agreement with Siemens Healthineers, as announced on 30 January 2025, of at least £8.2m (H1 2024: £nil). Accordingly, on an underlying basis, the Group expects to report revenue of at least £6.3m (H1 2025: £3.7m), representing growth of 70% over the first half of 2025. This was driven by strong growth in the CBRN Detection division as well as an increase in underlying revenue in the Advanced Imaging division.
공시 • Oct 03+ 1 more updateKromek Group plc, Annual General Meeting, Oct 27, 2025Kromek Group plc, Annual General Meeting, Oct 27, 2025. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham ts21 3ff, sedgefield United Kingdom
공시 • Sep 17Kromek Group plc Provides Earnings Guidance for the Fiscal Year 2026Kromek Group plc provided earnings guidance for the fiscal year 2026. For the year, the company expected to deliver further revenue growth and profitability, in line with market expectations.
공시 • May 10+ 1 more updateKromek Group plc Announces CFO Changes, Effective 1 June 2025Kromek Group plc announced that Claire Burgess will be appointed as Chief Financial Officer ("CFO") of the Group, effective June 1, 2025. Claire Burgess has spent over 12 years in senior financial positions in businesses in the UK and US, primarily in the engineering and technology sectors. Most recently, Ms. Burgess was Financial Director of Advanced Electric Machines Group Ltd. ("AEM"), a designer and manufacturer of magnet-free electric powertrain technologies. Other experience includes being CFO of group companies JB Processing and TBGS Holdings and being responsible for establishing and building the US subsidiaries, including the acquisition of the Alabama White Marble Quarry. She is a qualified Fellow Chartered Accountant, having begun her career as an auditor at Ernst & Young before joining KPMG as a Corporate Finance Executive. Paul Farquhar is retiring and will therefore resign as CFO of the Group, effective June 1, 2025. Claire Burgess, aged 51, Current directorships and/or partnerships Former directorships and/or partnerships (within the last 5 years): Advanced Electric Machines Group Limited; Advanced Electric Machines Limited; Advanced Electric Machines Research Limited; Inn Collection (Bassenthwaite) Limited; Inn Collection Lakes (Ambleside) Limited; Inn Collection (Whitby) Limited; Inn Collection (Northallerton) Limited; Inn Collection (Helmsley) Limited; Inn Collection (Seaburn) Limited; Inn Collection Lakes (Coniston) Limited; Vindolanda Bidco Limited; Lindisfarne Inns Limited; Inn Collection Limited; Inn Collection AcquisitionCo Limited; Inn Collection Topco Limited; Inn Collection Midco Limited; Durham Vale Developments Limited; Vindolanda Midco 1 Limited; Marshall Inns Limited; Greensfield Moor Development Limited; Lindisfarne Inns (Bamburgh Castle) Limited; Inn Collection Bidco Limited; Vindolanda Topco Limited; Vindolanda Midco 2 Limited; Inn Collection Management Limited; and Inn Collection Lakes (Ambleside) Limited.
공시 • Jan 30Kromek Group plc Provides Earnings Guidance for the Year 2025Kromek Group plc provided earnings guidance for the year 2025. For the period, the Group expects to become profitable, with profit significantly ahead of market expectations. The Group also expects to achieve further revenue growth beyond Fiscal Year 2025 while delivering sustainable profits.
공시 • Nov 19Kromek Group plc, Annual General Meeting, Dec 13, 2024Kromek Group plc, Annual General Meeting, Dec 13, 2024. Location: kromek biosecurity boardroom, explorer 1 building, north east technology park netpark, thomas wright way, county durham, ts21 3ff, sedgefield United Kingdom
New Risk • Nov 09New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risks Less than 1 year of cash runway based on current free cash flow (-UK£7.8m). Currently unprofitable and not forecast to become profitable next year (UK£3.4m net loss next year). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Market cap is less than US$100m (€50.6m market cap, or US$54.2m).
Buy Or Sell Opportunity • Oct 29Now 24% overvaluedOver the last 90 days, the stock has fallen 1.5% to €0.066. The fair value is estimated to be €0.053, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 17%. Revenue is forecast to grow by 31% in a year. Earnings are forecast to decline by 3.2% in the next year.
Reported Earnings • Oct 28Full year 2024 earnings released: UK£0.006 loss per share (vs UK£0.014 loss in FY 2023)Full year 2024 results: UK£0.006 loss per share (improved from UK£0.014 loss in FY 2023). Revenue: UK£19.4m (up 12% from FY 2023). Net loss: UK£3.29m (loss narrowed 46% from FY 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings.
New Risk • Aug 18New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended October 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported October 2023 fiscal period end). Currently unprofitable and not forecast to become profitable next year (UK£4.6m net loss next year). Share price has been volatile over the past 3 months (8.1% average weekly change). Shareholders have been diluted in the past year (5.3% increase in shares outstanding). Market cap is less than US$100m (€41.0m market cap, or US$45.2m).
Board Change • Mar 27Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 2 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Non-Executive Director Chris Wilks was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.